SCHEMBL12413719

SCHEMBL12413719

CC(C)CC(=O)N1CCCC(CN)C1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.41
KDM4E B2RXH2 2/20 0.41
TDP1 Q9NUW8 1/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
POLB P06746 2/20 0.41
LMNA P02545 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
ITGB3 P05106 2/20 0.40
ITGA2B P08514 2/20 0.40
JAK2 O60674 1/20 0.38
JAK1 P23458 1/20 0.38
HPGD P15428 2/20 0.38
NPC1 O15118 1/20 0.38
TSHR P16473 1/20 0.38
RAB9A P51151 1/20 0.38
MEN1 O00255 1/20 0.38
MAPT P10636 1/20 0.38
KMT2A Q03164 1/20 0.38
PTPN1 P18031 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12414842 0.90 SMN1; SMN2 (0.43) ALDH1A1KDM4ETDP1SMN1; SMN2POLB
SCHEMBL12413708 0.90 SMN1; SMN2 (0.43) ALDH1A1KDM4ETDP1SMN1; SMN2POLB
SCHEMBL13003387 0.87 ALDH1A1 (0.39) ALDH1A1SMN1; SMN2POLBLMNAITGB3
SCHEMBL15607434 0.86 LIPE (0.48) ALDH1A1KDM4ETDP1SMN1; SMN2POLB
SCHEMBL15566865 0.86 LIPE (0.48) ALDH1A1KDM4ETDP1SMN1; SMN2POLB
SCHEMBL15568328 0.86 LIPE (0.48) ALDH1A1KDM4ETDP1SMN1; SMN2POLB
SCHEMBL3399184 0.82 MEN1 (0.44) ALDH1A1POLBLMNAITGB3ITGA2B
SCHEMBL12413720 0.82 JAK2 (0.42) ALDH1A1KDM4ETDP1SMN1; SMN2POLB
SCHEMBL23710015 0.81 TLR9 (0.40) ALDH1A1LMNAITGB3ITGA2BDPP4
SCHEMBL12414840 0.81 SMN1; SMN2 (0.43) ALDH1A1KDM4ETDP1SMN1; SMN2POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8293729-B2 Compounds, pharmaceutical composition and methods relating thereto BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-10-23 US disclosed
US-8293729-B2 Compounds, pharmaceutical composition and methods relating thereto BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-10-23 US disclosed
US-20110166116-A1 NEW COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS RELATING THERETO BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-07-07 US disclosed
US-20110166116-A1 NEW COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS RELATING THERETO BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-07-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110166116-A1 NEW COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS RELATING THERETO MC2R, REN, CYP11B2 ALDH1A1 831/4885KDM4E 3718/4885TDP1 2755/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.